Cue Biopharma (CUE) Change in Account Payables (2017 - 2025)

Cue Biopharma has reported Change in Account Payables for 9 years, with the latest figure at $1.6 million in Q4 2025.

• Quarterly Change in Account Payables rose 143.86% year-over-year to $1.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.1 million (up 265.93% YoY) and the FY2025 annual result came in at $1.1 million, up 265.93% from the prior year.
• Change in Account Payables advanced to $1.6 million in Q4 2025 per CUE's latest filing, from -$1.3 million in the prior quarter.
• Over five years, Change in Account Payables peaked at $2.6 million in Q3 2024 and troughed at -$3.6 million in Q4 2024.
• A 5-year average of $91019.9 and a median of $163500.0 in 2021 frame the typical range for Change in Account Payables.
• The sharpest annual moves came in 2023 and 2024: Change in Account Payables slumped 2330.77% in 2023, then jumped 1970.16% in 2024.
• Over 5 years, Change in Account Payables stood at $120398.0 in 2021, then jumped by 422.43% to $629000.0 in 2022, then jumped by 62.32% to $1.0 million in 2023, then tumbled by 457.49% to -$3.6 million in 2024, then jumped by 143.86% to $1.6 million in 2025.
• According to Business Quant data, Change in Account Payables over the past three periods registered $1.6 million, -$1.3 million, and -$157000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.